Diclofenac etalhyaluronate sodium SR is a Small Molecule owned by Seikagaku, and is involved in 10 clinical trials, of which 7 were completed, and 3 are ongoing.

Diclofenac etalhyaluronate sodium is a formulation in which hyaluronic acid and a non-steroidal anti-inflammatory drug (NSAID) are chemically bound. NSAIDs work by blocking the production of certain body chemicals that cause inflammation. NSAIDs inhibit both isoforms of COX. The anti-inflammatory activity of the NSAIDs result primarily from COX-2 inhibition. Hyaluronic acid (HA) reduces nerve impulses and nerve sensitivity associated with the pain of osteoarthritis. HA enhances chondrocyte HA and proteoglycan synthesis, reduces the production and activity of proinflammatory mediators and matrix metalloproteinases, and alters the behavior of immune cells.

The revenue for Diclofenac etalhyaluronate sodium SR is expected to reach a total of $614m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Diclofenac etalhyaluronate sodium SR NPV Report.

Diclofenac etalhyaluronate sodium SR is originated and owned by Seikagaku. Ono Pharmaceutical is the other company associated in development or marketing of Diclofenac etalhyaluronate sodium SR.

Diclofenac etalhyaluronate sodium SR Overview

Diclofenac Etalhyaluronate Sodium (Joycle) is a non-steroidal anti-inflammatory agent. It is formulated as injectable solution for intra-articular route of administration. Joycle is indicated for the treatment of osteoarthritis (hip joint and knee joint).

Diclofenac etalhyaluronate sodium is under development for the treatment of Tachycardia (Tachyarrhythmias), osteoarthritis (knee,hip and ankle). The drug candidate is administered through intra-articular route. The drug candidate is a formulation of hyaluronic acid and a non-steroidal anti-inflammatory drug (NSAID) which is chemically bound by using Seikagaku's glycosaminoglycan (GAG) modification technology and drug binding technology. It is a sustained-release formulation. It was also under development for the treatment of enthesopathy which includes lateral epicondylitis and plantar fasciitis.

Ono Pharmaceutical Overview

Ono Pharmaceutical focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusions. Ono Pharmaceutical has three manufacturing facilities; Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.

The company reported revenues of (Yen) JPY361,361 million for the fiscal year ended March 2022 (FY2022), an increase of 16.8% over FY2021. In FY2022, the company’s operating margin was 28.6%, compared to an operating margin of 31.8% in FY2021. In FY2022, the company recorded a net margin of 22.3%, compared to a net margin of 24.4% in FY2021. The company reported revenues of JPY109,979 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Diclofenac etalhyaluronate sodium SR

Report Segments
  • Innovator (NME)
Drug Name
  • Diclofenac etalhyaluronate sodium SR
Administration Pathway
  • Intraarticular
Therapeutic Areas
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.